Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
11029341 | European Journal of Cancer | 2018 | 11 Pages |
Abstract
The majority of patients with advanced thyroid cancer had detectable ctDNA. ctDNA measurement may offer superiority over conventional markers in several scenarios: earlier detection of progression in MTC; as an alternative biomarker when conventional markers are not available; more rapid assessment of the disease status in response to targeted therapies, thereby potentially allowing prompter discontinuation of futile therapies. These early results support the hypothesis that ctDNA may be a clinically useful biomarker in thyroid cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
D.M. Allin, R. Shaikh, P. Carter, K. Thway, M.T.A. Sharabiani, D. Gonzales-de-Castro, B. O'Leary, I. Garcia-Murillas, S. Bhide, M. Hubank, K. Harrington, D. Kim, K. Newbold,